Skip to main content

Advertisement

Table 4 Deterioration status from baseline in each examination using reliable change index

From: The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases

Deterioration status RCT arm RT arm p
Deterioration No deterioration Deterioration No deterioration
At 3 months
 HVLT-R TR 21 84 19 68 0.76
 HVLT-R DR 23 82 32 55 0.02
 TMT Part A 22 81 25 63 0.26
 TMT Part B 24 79 33 55 0.03
 COWA 19 86 28 61 0.03
 FACT-L 23 79 24 61 0.45
At 5 months
 HVLT-R TR 21 511 33 31 0.008
 HVLT-R DR 23 49 35 29 0.007
 TMT Part A 18 52 25 37 0.07
 TMT Part B 21 49 30 32 0.03
 COWA 19 53 32 29 0.002
 FACT-L 25 48 36 29 0.01
At 7 months
 HVLT-R TR 20 22 19 17 0.65
 HVLT-R DR 24 18 17 19 0.38
 TMT Part A 23 21 21 15 0.59
 TMT Part B 25 19 22 14 0.70
 COWA 24 20 20 14 0.71
 FACT-L 24 17 21 12 0.66
  1. Abbreviations: HVLT-R TR Hopkins Verbal Learning Test total recall, HVLT-R DR Hopkins Verbal Learning Test delayed recall, TMT Trail-making Test, COWA Controlled Oral Word Association, FACT-L Functional Assessment of Cancer Treatment-Lung